Primary Site >> Stomach Cancer
Gene >> ERBB3
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ref: c-erbB3 gene encodes secreted as well as transmembrane receptor tyrosine kinase. PMID: 7685162 |
Ref: Expression of heregulin alpha, erbB2, and erbB3 and their influences on proliferation of gastric epithelial cells. PMID: 10535875 |
Ref: Identification of novel non-phosphorylated ligands, which bind selectively to the SH2 domain of Grb7. PMID: 11809769 |
Ref: Activation of ErbB3-PI3-kinase pathway is correlated with malignant phenotypes of adenocarcinomas. PMID: 12618754 |
Ref: Somatic mutations of the ERBB4 kinase domain in human cancers. PMID: 16187281 |
Ref: Macrophage inhibitory cytokine-1 activates AKT and ERK-1/2 via the transactivation of ErbB2 in human breast and gastric cancer cells. PMID: 18258606 Ref: FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival. PMID: 18381441 Ref: High expression of HER3 is associated with a decreased survival in gastric cancer. PMID: 19047113 |
Ref: Gene expression profiling in TWIST-depleted gastric cancer cells. PMID: 19051271 Ref: Comparative study on overexpression of HER2/neu and HER3 in gastric cancer. PMID: 19636613 Ref: Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells. PMID: 19755509 |
Ref: Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition. PMID: 20500904 Ref: Targeting the epidermal growth factor receptor (HER) family by T cell receptor gene-modified T lymphocytes. PMID: 20700725 |
Ref: Genomic and epigenetic profiles of gastric cancer: potential diagnostic and therapeutic applications. PMID: 21191688 Ref: Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft models. PMID: 21700765 Ref: Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome. PMID: 21709195 Ref: DARPP-32 increases interactions between epidermal growth factor receptor and ERBB3 to promote tumor resistance to gefitinib. PMID: 21741919 |
Ref: Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks. PMID: 21655918 Ref: Evaluation of the antitumor effects and mechanisms of PF00299804, a pan-HER inhibitor, alone or in combination with chemotherapy or targeted agents in gastric cancer. PMID: 22135232 |
Ref: Irinotecan resistance is accompanied by upregulation of EGFR and Src signaling in human cancer models. PMID: 22973964 Ref: HER3 overexpression and survival in solid tumors: a meta-analysis. PMID: 23221996 Ref: A novel proteomics-based clinical diagnostics technology identifies heterogeneity in activated signaling pathways in gastric cancers. PMID: 23372746 Ref: Y-box binding protein-1 contributes to both HER2/ErbB2 expression and lapatinib sensitivity in human gastric cancer cells. PMID: 23445612 Ref: Enhanced antitumor activity of trastuzumab emtansine (T-DM1) in combination with pertuzumab in a HER2-positive gastric cancer model. PMID: 23783223 Ref: Carboxyl group footprinting mass spectrometry and molecular dynamics identify key interactions in the HER2-HER3 receptor tyrosine kinase interface. PMID: 23843458 Ref: [Clinical significance of human epidermal growth factor receptor family molecules expression in gastric cancer]. PMID: 23888453 Ref: Combination of antibody that inhibits ligand-independent HER3 dimerization and a p110alpha inhibitor potently blocks PI3K signaling and growth of HER2+ breast cancers. PMID: 23918797 Ref: Gastric cancer-molecular and clinical dimensions. PMID: 24061039 Ref: Signal transduction of Helicobacter pylori during interaction with host cell protein receptors of epithelial and immune cells. PMID: 24280762 |
Ref: Prognostic value of epidermal growth factor receptors in gastric cancer: a survival analysis by Weibull model incorporating long-term survivors. PMID: 23455716 Ref: Testican-1-mediated epithelial-mesenchymal transition signaling confers acquired resistance to lapatinib in HER2-positive gastric cancer. PMID: 23873022 Ref: The ErbB2-targeting antibody trastuzumab and the small-molecule SRC inhibitor saracatinib synergistically inhibit ErbB2-overexpressing gastric cancer. PMID: 24492292 Ref: Her3 is associated with poor survival of gastric adenocarcinoma: Her3 promotes proliferation, survival and migration of human gastric cancer mediated by PI3K/AKT signaling pathway. PMID: 24623015 Ref: Unraveling trastuzumab and lapatinib inefficiency in gastric cancer: Future steps (Review). PMID: 24649329 Ref: Expression of the EGF family in gastric cancer: downregulation of HER4 and its activating ligand NRG4. PMID: 24728052 Ref: Lapatinib. PMID: 24756789 Ref: AKT/ERK activation is associated with gastric cancer cell resistance to paclitaxel. PMID: 24817940 Ref: Mutational and expressional analysis of ERBB3 gene in common solid cancers. PMID: 24909266 Ref: Functional genetic approach identifies MET, HER3, IGF1R, INSR pathways as determinants of lapatinib unresponsiveness in HER2-positive gastric cancer. PMID: 24973425 Ref: The role of HER3 in gastric cancer. PMID: 25194439 Ref: Expression of acidosis-dependent genes in human cancer nests. PMID: 25279216 Ref: Regulation of ERBB3/HER3 signaling in cancer. PMID: 25400118 Ref: Immunohistochemical analysis of RTKs expression identified HER3 as a prognostic indicator of gastric cancer. PMID: 25455899 |
Ref: Combination of novel HER2-targeting antibody 1E11 with trastuzumab shows synergistic antitumor activity in HER2-positive gastric cancer. PMID: 25306393 Ref: Essential role of Her3 in two signaling transduction patterns: Her2/Her3 and MET/Her3 in proliferation of human gastric cancer. PMID: 25400108 Ref: Assessment and prognostic analysis of EGFR, HER2, and HER3 protein expression in surgically resected gastric adenocarcinomas. PMID: 25565860 Ref: Multiple receptor tyrosine kinase activation attenuates therapeutic efficacy of the fibroblast growth factor receptor 2 inhibitor AZD4547 in FGFR2 amplified gastric cancer. PMID: 25576915 Ref: Protein expression of HER2, 3, 4 in gastric cancer: correlation with clinical features and survival. PMID: 25731189 Ref: Patient-Derived Gastric Carcinoma Xenograft Mouse Models Faithfully Represent Human Tumor Molecular Diversity. PMID: 26217940 Ref: Pyrosequencing-Based Assays for Rapid Detection of HER2 and HER3 Mutations in Clinical Samples Uncover an E332E Mutation Affecting HER3 in Retroperitoneal Leiomyosarcoma. PMID: 26287187 Ref: Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas. PMID: 26296355 Ref: HER3 over-expression and overall survival in gastrointestinal cancers. PMID: 26517355 |
Ref: Pertuzumab in gastrointestinal cancer. PMID: 26619359 Ref: Preclinical evidence of multiple mechanisms underlying trastuzumab resistance in gastric cancer. PMID: 26919099 Ref: APIP, an ERBB3-binding partner, stimulates erbB2-3 heterodimer formation to promote tumorigenesis. PMID: 26942872 Ref: HER Family Protein Expression in a Greek Population with Gastric Cancer. A Retrospective Hellenic Cooperative Oncology Group Study. PMID: 27069134 Ref: Comprehensive mutation profiling of mucinous gastric carcinoma. PMID: 27313181 Ref: The anti-HER3 antibody in combination with trastuzumab exerts synergistic antitumor activity in HER2-positive gastric cancer. PMID: 27317872 Ref: A Phase II Biomarker-Embedded Study of Lapatinib plus Capecitabine as First-line Therapy in Patients with Advanced or Metastatic Gastric Cancer. PMID: 27325685 Ref: HER3, but Not HER4, Plays an Essential Role in the Clinicopathology and Prognosis of Gastric Cancer: A Meta-Analysis. PMID: 27536774 Ref: The prospect of patritumab for treating non-small cell lung cancer. PMID: 27744717 Ref: Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1. PMID: 27768588 Ref: Increased expression of EHF via gene amplification contributes to the activation of HER family signaling and associates with poor survival in gastric cancer. PMID: 27787520 |
Ref: LJM716 in Japanese patients with head and neck squamous cell carcinoma or HER2-overexpressing breast or gastric cancer. PMID: 27942917 Ref: HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target? PMID: 27981460 Ref: Expression of the ERBB Family of Ligands and Receptors in Gastric Cancer. PMID: 28399526 Ref: Sporadic Early-Onset Diffuse Gastric Cancers Have High Frequency of Somatic CDH1 Alterations, but Low Frequency of Somatic RHOA Mutations Compared With Late-Onset Cancers. PMID: 28522256 Ref: siRNA-mediated inactivation of HER3 improves the antitumour activity and sensitivity of gefitinib in gastric cancer cells. PMID: 28881753 Ref: A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer. PMID: 28899363 Ref: SNP rs3202538 in 3'UTR region of ErbB3 regulated by miR-204 and miR-211 promote gastric cancer development in Chinese population. PMID: 28924391 Ref: Prognostic significance of HER3 in patients with malignant solid tumors. PMID: 28978022 Ref: Positive prognostic value of HER2-HER3 co-expression and p-mTOR in gastric cancer patients. PMID: 29233126 |
Ref: Clinical significance of overexpression of NRG1 and its receptors, HER3 and HER4, in gastric cancer patients. PMID: 28573357 Ref: 4-Phenybutyric acid promotes gastric cancer cell migration via histone deacetylase inhibition-mediated HER3/HER4 up-regulation. PMID: 28851073 Ref: Expression and prognostic significance of human epidermal growth factor receptors 1, 2 and 3 in oesophageal and gastric adenocarcinomas preneoadjuvant and postneoadjuvant treatment. PMID: 29138285 Ref: Mechanisms for DNA-damaging agent-induced inactivation of ErbB2 and ErbB3 via the ERK and p38 signaling pathways. PMID: 29434871 Ref: Acquired Resistance to a MET Antibody In Vivo Can Be Overcome by the MET Antibody Mixture Sym015. PMID: 29545332 Ref: Rates of TP53 Mutation are Significantly Elevated in African American Patients with Gastric Cancer. PMID: 29725898 Ref: Landscape of somatic mutations in gastric cancer assessed using next-generation sequencing analysis. PMID: 30250552 |